Leiserowitz, Gary S.
https://orcid.org/0000-0002-3016-4490
Mayo Clinic
UC Davis Comprehensive Cancer Center
Citations 2
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Cohen, Joshua G. , Miller, David S. , Robertson, Sharon E. , Hendrickson, Andrea Wahner, Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Konecny, Gottfried E. , Moroney, John W. , Ratner, Elena , Schorge, John O., Werner, Theresa L. , Chen, Lee-may, DeRosa, Marie, Eisenhauer, Eric , Leiserowitz, Gary S. , Litkouhi, Babak , McHale, Michael , Percac‐Lima, Sanja , Rodabaugh, Kerry J. , Vargas, Roberto , Jones, Frankie, Kovách, E, Hang, Lisa E., Ramakrishnan, Swathi , Armstrong, Deborah K. , Miller, David S , Liu, Joyce F. , Berchuck, Andrew , Backes, Floor , Grisham, Rachel Nicole , Leath, Charles A , Martin, Lainie P. , Matei, Daniela , Barroilhet, Lisa , Uppal, Shitanshu , Gershenson, David M. , Thaker, Premal H. , Zsíros, Emese , Behbakht, Kian , Kovach, Emily, Alvarez, Ronald D.
Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 512-519
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Armstrong, Deborah K. , Barroilhet, Lisa , Chitiyo, Viola C., Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , McHale, Michael , Miller, David S. , Percac‐Lima, Sanja , Remmenga, Steven W., Schorge, John O., Vargas, Roberto , Hendrickson, Andrea Wahner, Werner, Theresa L. , Dwyer, Mary A., Hang, Lisa E., Miller, David S , Alvarez, Ronald D. , Backes, Floor , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Chitiyo, Viola, DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Leiserowitz, Gary S. , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen , Stewart, Daphne B. , Thaker, Premal H. , Zsíros, Emese
Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 972-980
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.